Scarica l'app Stockscreener
234.94
0.28%
-1.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$235.97
Aprire:
$236.79
Volume 24 ore:
261.14K
Relative Volume:
0.37
Capitalizzazione di mercato:
$12.10B
Reddito:
$708.24M
Utile/perdita netta:
$-188.30M
Rapporto P/E:
-62.83
EPS:
-3.7392
Flusso di cassa netto:
$-70.99M
1 W Prestazione:
+3.81%
1M Prestazione:
+26.54%
6M Prestazione:
+55.85%
1 anno Prestazione:
+123.95%
Intervallo 1D:
$233.63
$238.56
Intervallo di 1 settimana:
$224.00
$238.56
Portata 52W:
$96.09
$238.56
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
235.11 | 12.14B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
436.35 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.49 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.00 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.23 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
New AUVELITY depression data, sleep apnea study head to ASCP 2026 - Stock Titan
Axsome Therapeutics, Inc. $AXSM Shares Acquired by Legato Capital Management LLC - MarketBeat
Axsome Therapeutics stock hits all-time high at 236.84 USD By Investing.com - Investing.com Nigeria
Axsome Therapeutics Climbs Higher On Nasdaq Momentum - Kalkine Media
Technical Reactions to AXSM Trends in Macro Strategies - Stock Traders Daily
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Axsome Therapeutics stock hits all-time high at 236.84 USD - Investing.com
AXSM Stock Price, Quote & Chart | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome wins FDA label expansion for Auvelity in Alzheimer’s agitation - MSN
AXSM Technical Analysis | Trend, Signals & Chart Patterns | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
AXSM: June launch of new Alzheimer's agitation drug, expanded sales force, and robust pipeline progress - TradingView
Axsome Therapeutics (AXSM) price target increased by 18.66% to 272.70 - MSN
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: High Growth Potential with 18.69% Upside - DirectorsTalk Interviews
Why is Axsome (AXSM) down 6.6% since last earnings report? - MSN
Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch - MSN
AXSM stock clocks best day in about 4 months on FDA greenlight for Alzheimer’s drug - MSN
Axsome Therapeutics bets on AUVELITY expansion with June Alzheimer's agitation launch - MSN
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome's Auvelity: A New Treatment For Agitation In Alzheimer's Disease (AXSM) - Seeking Alpha
AXSM Stock Chart | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome Therapeutics stock hits all-time high at 234.57 USD - Investing.com India
Axsome Therapeutics stock hits all-time high at 234.57 USD By Investing.com - Investing.com Nigeria
AXSM stock is rising today after Wall Street’s positive stance despite mixed Q1 – what's behind the optimism? - MSN
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch - sharewise.com
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258 - Moomoo
Strong drug sales lift Axsome revenue, but profit miss drags stock - MSN
Trading the Move, Not the Narrative: (AXSM) Edition - Stock Traders Daily
White & Case advises Takeda on divestment to Axsome Therapeutics - White & Case LLP
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Understanding the 24% Potential Upside in CNS Treatments - DirectorsTalk Interviews
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target - Investing.com Nigeria
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target By Investing.com - Investing.com South Africa
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results By Investing.com - Investing.com Australia
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results - Investing.com
The week in pharma: action, reaction and insight – week to May 8, 2026 - The Pharma Letter
Axsome Therapeutics, Inc. $AXSM Holdings Decreased by State of New Jersey Common Pension Fund D - MarketBeat
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310 - Moomoo
3 Stocks Poised to Disrupt the Healthcare Market by 2030 - The Motley Fool
Principal Financial Group Inc. Lowers Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Option Exercise |
12.95 |
233 |
3,017 |
233 |
| Jacobson Mark L. | Chief Operating Officer |
May 04 '26 |
Sale |
227.94 |
4,517 |
1,029,605 |
0 |
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Sale |
228.18 |
233 |
53,166 |
0 |
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):